ProductNum | picture | CAS No. | Name and description | Size | Formula | Quick order |
---|---|---|---|---|---|---|
GC39648-5mg |
|
2194903-42-7 |
H3B-120
|
0 | C19H24N4O2S | |
GC39647-100mg |
|
1055411-77-2 |
Dopamine D2 receptor antagonist-1
|
0 | C14H17N3S | |
GC39647-50mg |
|
1055411-77-2 |
Dopamine D2 receptor antagonist-1
|
0 | C14H17N3S | |
GC39647-10mg |
|
1055411-77-2 |
Dopamine D2 receptor antagonist-1
|
0 | C14H17N3S | |
GC39647-5mg |
|
1055411-77-2 |
Dopamine D2 receptor antagonist-1
|
0 | C14H17N3S | |
GC39646-100mg |
|
187739-60-2 |
Carboxyamidotriazole Orotate
|
0 | C22H16Cl3N7O6 | |
GC39646-50mg |
|
187739-60-2 |
Carboxyamidotriazole Orotate
|
0 | C22H16Cl3N7O6 | |
GC39646-10mg |
|
187739-60-2 |
Carboxyamidotriazole Orotate
|
0 | C22H16Cl3N7O6 | |
GC39646-5mg |
|
187739-60-2 |
Carboxyamidotriazole Orotate
|
0 | C22H16Cl3N7O6 | |
GC39645-100mg |
|
1613191-99-3 |
ATR inhibitor 2
|
0 | C25H29F2N9O3 | |
GC39645-50mg |
|
1613191-99-3 |
ATR inhibitor 2
|
0 | C25H29F2N9O3 | |
GC39645-10mg |
|
1613191-99-3 |
ATR inhibitor 2
|
0 | C25H29F2N9O3 | |
GC39645-5mg |
|
1613191-99-3 |
ATR inhibitor 2
|
0 | C25H29F2N9O3 | |
GC39644-50mg |
|
2127109-85-5 |
Tyk2-IN-9
|
0 | C20H17N9 | |
GC39644-10mg |
|
2127109-85-5 |
Tyk2-IN-9
|
0 | C20H17N9 | |
GC39644-5mg |
|
2127109-85-5 |
Tyk2-IN-9
|
0 | C20H17N9 | |
GC39643-50mg |
|
70962-66-2 |
Sparfosic acid trisodium
|
0 | C6H7NNa3O8P | |
GC39643-10mg |
|
70962-66-2 |
Sparfosic acid trisodium
|
0 | C6H7NNa3O8P | |
GC39643-5mg |
|
70962-66-2 |
Sparfosic acid trisodium
|
0 | C6H7NNa3O8P | |
GC39642-50mg |
|
888958-26-7 |
SARS-CoV-IN-2
|
0 | C24H18ClFeN3O | |